Novartis ( NVS) has agreed to acquire Nektar Therapeutics' ( NKTR) pulmonary business for $115 million in cash.

The Swiss drug maker will assume ownership of certain dry powder and liquid pulmonary formulation and manufacturing assets. The agreement also transfers to Novartis about 140 Nektar personnel.

The transaction excludes Nektar's inhalation programs for insulin, vancomycin, ciprofloxacin and amikacin, Novartis said in a press release Tuesday.

The deal is expected to be completed on Dec. 31.

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains
Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias